Histamine & Moi: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Histamine & Moi
Largest movements
- Receivables within one year +€4,200
up €4,200 (+30.6%), from €13,703 to €17,903
of which Trade receivables: +€4,641
- Intangible fixed assets -€3,097
down €3,097 (-55.5%), from €5,580 to €2,482
- Cash +€1,208
up €1,208 (+23.1%), from €5,231 to €6,439
mainly Trade debts (+€3,281) and Depreciation (+€3,097)
- Deferred charges and accrued income +€534
up €534 (+143.9%), from €371 to €905
- Trade debts +€3,281
up €3,281 (+94.9%), from €3,456 to €6,738
- Other debts -€1,093
down €1,093 (-19.1%), from €5,718 to €4,624
- Tax, wage and social debts +€416
up €416 (+18.2%), from €2,288 to €2,704
- Gross operating margin -€4,716
down €4,716 (-53.9%), from €8,746 to €4,030
- Other operating charges -€788
no longer reported in 2025 (was €788)
- Taxes -€732
down €732 (-59.6%), from €1,228 to €496
- Depreciation +€496
up €496 (+19.1%), from €2,601 to €3,097
- Financial income -€414
down €414 (-90.8%), from €456 to €42
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €24,885 | €27,729 | +€2,844 | +11.4% |
| Fixed assets | 21/28 | €5,580 | €2,482 | -€3,097 | -55.5% |
| Intangible fixed assets | 21 | €5,580 | €2,482 | -€3,097 | -55.5% |
| Current assets | 29/58 | €19,305 | €25,247 | +€5,941 | +30.8% |
| Amounts receivable within one year | 40/41 | €13,703 | €17,903 | +€4,200 | +30.6% |
| Trade receivables | 40 | €3,434 | €8,075 | +€4,641 | +135.2% |
| Other amounts receivable | 41 | €10,269 | €9,828 | -€441 | -4.3% |
| Cash at bank and in hand | 54/58 | €5,231 | €6,439 | +€1,208 | +23.1% |
| Deferred charges and accrued income | 490/1 | €371 | €905 | +€534 | +143.9% |
| Total equity and liabilities | 10/49 | €24,885 | €27,729 | +€2,844 | +11.4% |
| Equity | 10/15 | €13,423 | €13,663 | +€240 | +1.8% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €8,423 | €8,663 | +€240 | +2.9% |
| Amounts payable | 17/49 | €11,462 | €14,066 | +€2,604 | +22.7% |
| Amounts payable within one year | 42/48 | €11,462 | €14,066 | +€2,604 | +22.7% |
| Trade debts | 44 | €3,456 | €6,738 | +€3,281 | +94.9% |
| Suppliers | 440/4 | €3,456 | €6,738 | +€3,281 | +94.9% |
| Taxes, remuneration and social security | 45 | €2,288 | €2,704 | +€416 | +18.2% |
| Taxes | 450/3 | €2,288 | €2,704 | +€416 | +18.2% |
| Other amounts payable | 47/48 | €5,718 | €4,624 | -€1,093 | -19.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,601 | €3,097 | +€496 | +19.1% |
| Other operating charges | 640/8 | €788 | - | -€788 | |
| Gross operating margin | 9900 | €8,746 | €4,030 | -€4,716 | -53.9% |
| Operating profit (loss) | 9901 | €5,357 | €933 | -€4,424 | -82.6% |
| Financial income | 75/76B | €456 | €42 | -€414 | -90.8% |
| Recurring financial income | 75 | €456 | €42 | -€414 | -90.8% |
| Financial charges | 65/66B | €379 | €239 | -€140 | -36.9% |
| Recurring financial charges | 65 | €379 | €239 | -€140 | -36.9% |
| Profit (loss) for the period before taxes | 9903 | €5,434 | €736 | -€4,698 | -86.5% |
| Income taxes | 67/77 | €1,228 | €496 | -€732 | -59.6% |
| Profit (loss) for the period | 9904 | €4,206 | €240 | -€3,966 | -94.3% |
| Profit (loss) for the period to be appropriated | 9905 | €4,206 | €240 | -€3,966 | -94.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.